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Abstract
Background: Overexpression of the gastrin-releasing peptide receptor (GRP-R) has been documented in several
human neoplasms such as breast, prostate, and ovarian cancer. There is growing interest in developing radiolabeled
peptide-based ligands toward these receptors for the purpose of in vivo imaging and radionuclide therapy of GRP-
R-overexpressing tumors. A number of different peptide sequences, isotopes, and labeling methods have been
proposed for this purpose. The aim of this work is to perform a direct side-by-side comparison of different GRP-R
binding peptides utilizing a single labeling strategy to identify the most suitable peptide sequence.
Methods: Solid-phase synthesis of eight derivatives (BN1-8) designed based on literature analysis was carried out.
Peptides were coupled to the DOTA chelator through a PEG4 spacer at the N-terminus. Derivatives were
characterized for serum stability, binding affinity on PC-3 human prostate cancer cells, biodistribution in tumor-
bearing mice, and gamma camera imaging at 1, 6, and 24 h after injection.
Results: Serum stability was quite variable among the different compounds with half-lives ranging from 16 to
400 min at 37 °C. All compounds tested showed Kd values in the nanomolar range with the exception of BN3 that
showed no binding. Biodistribution and imaging studies carried out for compounds BN1, BN4, BN7, and BN8
showed targeting of the GRP-R-positive tumors and the pancreas. The BN8 compound (DOTA-PEG-DPhe-Gln-Trp-
Ala-Val-NMeGly-His-Sta-Leu-NH2) showed high affinity, the longest serum stability, and the highest target-to-
background ratios in biodistribution and imaging experiments among the compounds tested.
Conclusions: Our results indicate that the NMeGly for Gly substitution and the Sta-Leu substitution at the C-
terminus confer high serum stability while maintaining high receptor affinity, resulting in biodistribution properties
that outperform those of the other peptides.
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Background
The bombesin receptor family consists of four receptor
subtypes (BB1, BB2/GRP, BB3, and BB4) [1]. Overex-
pression of the first two members of this family has been
documented in several human neoplasms such as breast,
prostate, and ovarian cancer and is of interest for diag-
nostic and therapeutic nuclear medicine applications [2].
In patients with prostate cancer, there is very promising
preliminary clinical data pointing to the use of radiola-
beled gastrin-releasing peptide receptor (GRP-R) ligands
for detecting metastatic disease and monitoring disease
progression [3, 4]. There is also great interest in devel-
oping peptide receptor radionuclide therapy (PRRT)
strategies with the same approach given the high uptake
values found in metastatic lesions. Initially, the GRP-R
agonist AMBA [5] showed promising results for success-
ful clinical use; however, its agonistic activity has caused
acute gastrointestinal side effects such as nausea, ab-
dominal pain, and emesis and its overall efficacy has
been rather unsatisfactory in a phase I trial [6]. Later
work has focused on the development of receptor antag-
onists that have the advantage of showing higher specific
uptake compared to agonists and none of the gastro-
intestinal side effects shown by agonists [7]. Efforts are
made to identify optimal ligands that, labeled with ap-
propriated radionuclides (e.g., 68Ga for PET imaging and
177Lu for therapy), can be used for imaging and therapy
applications in a “theranostic” approach.
Several radiolabeled bombesin agonists and antago-
nists have been described in recent years where numer-
ous peptide sequences and chelation systems have been
extensively studied. Optimization of different labeling
strategies and modification of the peptide structures
aimed at improving stability, pharmacokinetic, and bind-
ing properties of the peptides have been addressed. Most
of the derivatives are based on the peptide sequence of
truncated bombesin, bombesin (7-14) (BN(7-14): Gln-
Trp-Ala-Val-Gly-His-Leu-Met-NH2), that retains high
affinity for the GRP-R [8].
Modifications in key positions of BN(7-14) are crucial
not only to stabilize the derivatives or to increase the
binding affinity but also in determining whether these
molecules have agonist or antagonist properties. A com-
prehensive summary of these studies has been reported
by Jensen et al. [9]. The methionine on the C-terminus
(Met14) is sensitive to oxidation and has been substituted
with norleucine (Nle) [10–12]. The replacement of Leu13
with Cha13 has shown to improve overall stability and in
vivo targeting ability of the peptide [13]. The His12/
Leu13 bond is sensitive to cleavage by neutral endopep-
tidase [14], so substitution of Leu for the non-natural
Cha and Sta (see below) has been suggested to increase
in vivo stability [15]. The Gly11-His12 bond is sensitive to
carnosinase enzymatic cleavage [16] and therefore Gly11
has been substituted with N-methylglycine in previous
reports [15]. Finally, the presence of DPhe at the N-
terminus and the substitution of the Leu13 with the unnat-
ural aminoacid Sta13 seem to confer antagonistic behavior
to the new analogs [17]. Bombesin receptor antagonists
are shown to be superior to agonists in terms of higher
tumor accumulation, longer tumor retention, and better
tumor-to-tissue ratios [7, 18, 19].
The introduction of a spacer between the chelator and
the peptide is an important feature since it can modulate
the stability, affinity, and pharmacokinetics of the bom-
besin derivatives. It has been shown that polyethylene
glycol moieties of different lengths improve pharmaco-
kinetics of bombesin derivatives [20–23], although they
may negatively affect affinity and internalization rates
[23, 24].
All of the above described modifications have been pre-
viously described using different labeling strategies and
methods to characterize in vitro and in vivo biological
properties. Our current goal is to investigate the import-
ance of the peptide sequence in determining overall
biological properties of the previously described com-
pounds. To achieve this, we have synthesized and char-
acterized eight different derivatives that have been
coupled at the N-terminus with the DOTA chelator
through a PEG4 (15-amino-4,7,10,13-tetraoxapentade-
canoic acid) spacer in order to use the same labeling
strategy for all. We have performed in vitro and in vivo
experiments (such as stability, binding affinity, biodis-
tribution, and tumor targeting) to obtain a side-by-side
comparison of these compounds to determine which of
these peptide sequences is more suitable for in vivo use.
Methods
Reagents
Protected Nα-Fmoc-amino acid derivatives, coupling
reagents, and Rink amide 4-methylbenzhydrylamine
(MBHA) resin were purchased from Calbiochem-
Novabiochem (Laufelfingen, Switzerland). The Fmoc-21-
amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid (Fmoc
-Ahoh-OH) and Fmoc-8-amino-3,6-dioxaoctanoic acid
(Fmoc-AdOO-OH) were purchased from Neosystem
(Strasbourg, France). DOTA(OtBu)3-OH (1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetraacetate tert-butyl ester)
was purchased from CheMatech (Dijon, France). Citrate
acid, sodium citrate, and sodium chloride were obtained
from Sigma-Aldrich Corp. (St. Louis, MO, USA). All
other chemicals were commercially available by Sigma-
Aldrich, Fluka (Bucks, Switzerland) or LabScan (Stillorgan,
Dublin, Ireland) and were used as received unless otherwise
stated. Preparative HPLCs were carried out on a LC8
Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan)
equipped with a UV Lambda-Max Model 481 detector.
UV-Vis measurements were carried out on Thermo Fisher
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Scientific Inc. (Wilmington, Delaware USA) Nanodrop
2000c spectrophotometer equipped with a 1.0-cm quartz
cuvette (Hellma). 177LuCl3 and
111InCl3 were obtained
from IDB (Petten, The Netherlands) and Mallinckrodt
Radiopharmaceuticals Italia (Segrate, Italy), respectively.
DOTA-PEG4-BN peptide syntheses
All peptide conjugates were synthesized according to the
standard solid-phase techniques with Fmoc/tBu proto-
cols using a Syro I MultiSynThec GmbH (Wullener,
Germany) automatic synthesizer. Rink-amide MBHA
resin (0.78 mmol/g, 0.5 mmol scale, 0.640 g) was used.
Elongation of the BN analogs was achieved by serial
addition of 4 equivalents of Fmoc-AA-OH, 4 equivalents
of the coupling reagents PyBOP/HOBt (benzotriazol-1-
yl-oxytripyrrolidinophosphonium hexafluorophosphate/
1-hydroxy-1,2,3-benzotriazole), and 8 equivalents of N,N-
diisopropylethylamine (DIPEA) (1:1:2) in dimethylforma-
mide (DMF). Each coupling was performed twice leaving
the mixture under stirring for 30 min. Deprotection of the
Fmoc group from the N-terminus of the sequence was
achieved with 2 cycles (7 min each) of a piperidine solu-
tion in DMF (70/30 v/v). When the bombesin sequences
were complete, and the last Fmoc N-terminal protecting
group removed, two residues of Fmoc-AdOO-OH and the
DOTA(OtBu)3-OH chelating agent were condensed as
previously described [25]. For the deprotection and cleav-
age, the peptidyl resins were treated with trifluoroacetic
acid (TFA) containing 2.5 % triisopropylsilane (TIS) (v/v)
and 2.5 % water (v/v) as scavengers for 2 h. Then, crude
peptide conjugates were precipitated at 0 °C by adding
cold ether dropwise and lyophilized. Purification was
Fig. 1 Schematic representation of BN peptide conjugates DOTA-PEG4-BN. BN sequences are here indicated using the three-letter amino acid
code. Substitutions with respect to the wild-type BN[7–14] and addition at the C- or N-terminus are also shown
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carried out by RP-HPLC (λ = 280 nm) on a LC8 Shimadzu
HPLC system (Shimadzu Corporation, Kyoto, Japan)
equipped with a UV Lambda-Max Model 481 detector
using a Phenomenex (Torrance, CA) C18 (300 Å, 250 ×
21.20 mm, 5 μ) column eluted with H2O/0.1 % TFA (A)
and CH3CN/0.1 % TFA (B) from 5 to 70 % over 30 min at
a flow rate of 20 mL min−1. Figure 1 shows a schematic
representation of the different peptide sequences synthe-
sized and highlights how they have been modified from
the wild-type bombesin octapeptide BN[7–14] (BN1).
Purity and identity of the products (see Table 1) were
assessed by LC-MS analyses using Finnigan Surveyor
MSQ single quadrupole electrospray ionization (Finnigan/
Thermo Electron Corporation, San Jose, CA) equipped
with a C18-Phenomenex column (250 × 4.6 mm). Each
peptide solution was eluted with H2O/0.1 % TFA (A) and
CH3CN/0.1 % TFA (B) from 5 to 70 % over 15 min at
250 μL min−1 flow rate. The yields of the peptides after
the purification ranged between 60 and 80 % and purity
degree, obtained by integrating the HPLC areas, higher
than 97 %.
Serum stability
Serum stability experiments were carried out on 177Lu-
labeled peptides due to weekly availability of this isotope
in the laboratory where the experiments were per-
formed. All the 177Lu-labeled conjugates were obtained
dissolving 10 μg peptide in ammonium acetate buffer
(300 μl, 0.4 M, pH 5.5) and incubating for 30 min at 95 °
C with 177LuCl3 (100–180 MBq). Quality controls to de-
termine the labeling yield and the radiochemical purity
were performed using radio-HPLC. Radiolabeled pep-
tides were utilized without further purification. To 1 mL
of freshly prepared human serum, previously equili-
brated in a 5 % CO2 environment at 37 °C, we added
0.6 nmol of the 177Lu-labeled peptide. The mixture was
incubated in a 5 % CO2, 37 °C. At different time points,
100 μL aliquots (in triplicates) were removed and treated
with 200 μL of EtOH to precipitate serum proteins.
Samples were then centrifuged for 15 min at 5000 rpm
(2655g). After centrifugation, 50 μL of supernatant was
removed and counted in a γ-well counter; the sediment
was washed twice with 1 mL of EtOH and counted. The
activity in the supernatant was compared with the activ-
ity in the pellet to obtain the percentage of peptide not
bound to proteins or radiometal transferred to serum
proteins. The supernatant was also analyzed with radio-
HPLC (eluents: A = 0.1 % trifluoroacetic acid in water and
B = acetonitrile; gradient 0–25 min 95–50 % B) to deter-
mine the relative amount of intact peptide and its metabo-
lites in the serum. The half-life was calculated fitting a
first-order reaction to the experimental data (Equation 1)
using Prism software (GraphPad Software Inc.).
Saturation binding experiments
DOTA-PEG4-BN conjugates were studied in vitro per-
forming saturation binding experiments on whole cells.
The DOTA coupled derivatives were labeled in Eppendorf
tubes containing 10 μL of 111InCl3 (50–150 KBq/μL),
1 nmol of peptide (10 μM final concentration), and
sodium acetate buffer (0.4 M, pH 5) adjusted to a final
volume of 100 μL. The solution was incubated for 30 min
at 95 °C in a heating block. Silica gel thin layer chromatog-
raphy using 0.1 N sodium citrate (pH 5) as mobile phase
was utilized for quality control. Radiochemical purity was
>98 %. Saturation of free chelators with cold indium was
not performed. Confluent PC-3 human prostate cancer
cells were seeded in six-well plates (~1.0 × 106 cells) 24 h
before starting the experiments. Increasing concentrations
of the 111In-DOTA-peptide ranging from 50 to 0.05 nM
were assigned to different wells. For blocking experiments,
excess of the respective unlabeled peptide was used. For
each radioligand, triplicates were prepared for every con-
centration, for both total binding and nonspecific binding.
Before adding the radioligands to the wells, the plates
were placed on ice for 30 min. After adding the radioli-
gands and the blocking for nonspecific binding, the plates
were incubated for 1 h at 4 °C. Afterwards, the binding
buffer was removed and the cells were washed twice with
ice-cold phosphate-buffered saline (PBS; pH 7.4). Cell-
Table 1 Peptide conjugates with their corresponding peptide sequence, retention time (Rt), molecular weight (MW), and LC-MS
data. All peptides contain DOTA-PEG4 on the N-terminus
Peptide conjugates Peptide sequence Rt/min MW/u.m.a. [M + 2H
+]/2
BN1 -Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 12.91 1595 797.4
BN2 -Gln-Trp-Ala-Val-Gly-His-Cha-Nle-NH2 13.66 1630 817.6
BN3 -Gln-Trp-Ala-Val-Gly-His-Cha-Nle-Glu-NH2 13.55 1759 880.7
BN4 -Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 12.56 1636 819.3
BN5 -Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2 12.46 1649 825.4
BN6 -DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 13.19 1783 891.4
BN7 -DPhe-Gln-Trp-Ala-Val-Gly-His-Cha-Nle-NH2 14.35 1780 891.5
BN8 -DPhe-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2 13.13 1798 900.3
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bound radioactivity was subsequently recovered by trypsi-
nization of the wells. Radioactivity in the bound and free
fractions was determined with a WIZARD gamma coun-
ter (Wallac, Turku, Finland). Specific binding was calcu-
lated by subtracting nonspecific from total binding at each
concentration of radioligand. Affinity (Kd) and binding site
density (Bmax) were calculated from Scatchard plots using
Prism software (GraphPad Software Inc.).
Biodistribution and imaging experiments in nude mice
bearing subcutaneous PC-3 xenografts
For animal experiments, the institutional and national
guide for the care and use of laboratory animals was
followed. CD1 nude mice (n = 36, female, 6 weeks old,
18–22 g body weight) were subcutaneously injected in the
right thigh with 2 × 106 PC-3 cells in 300 μl of a medium-
to-matrigel solution (50:50, v:v, BD Biosciences). After
tumor growth (approximately 20 days), mice were divided
in four groups (BN1, BN4, BN7, and BN8). DOTA-PEG4-
BN conjugates were radiolabelled with 111In as described
elsewhere [26], and 1.85 MBq (0.25 μg, 7.4 MBq/μg in
100 μl NaCl) of radiopharmaceutical was injected in the
tail vein of each animal. Injected dose was determined by
counting the syringe before and after injection. At 1 h post
injection, three mice per group were anesthetized and
placed on a horizontal support for planar imaging. The
same procedure was repeated at 6 h and 24 h post injec-
tion. Images were acquired for 60 to 90 s with a high-
resolution scintigraphic camera [27] equipped with a
square tungsten collimator integrated with a CsI(Tl) scin-
tillation structure, coupled to a Hamamatsu H8500 Flat
Panel Position Sensitive Photomultiplier Tube (PSPMT), a
pure tungsten shielding housing, a charge readout elec-
tronics, and a data acquisition system for online image
display. Region of interest (ROI) analysis was performed
by drawing a region over the visible tumor (target) and
copying it to the opposite thigh (background). The counts
in the tumor ROI divided by the counts in the background
ROI provided tumor-to-background (T/B) ratios. After
each imaging session, mice were euthanized. The organs
and the tumors were excised and weighed, and the radio-
activity was determined using a single well γ-counter.
Results were expressed as percentage of injected dose per
gram (%ID/g) of tissue.
Results
Serum stability and saturation binding experiments
Saturation binding experiments were performed on PC-
3 cells at 4 °C. The results are summarized in Table 2.
With the exception of the BN3 derivative for which no
specific binding was detectable, all compounds showed
saturable binding with Kd in the order of 10
−9 M and
Bmax values in the order of 10
5 receptor sites per cell.
Figure 2 shows a time course analysis of the stability
of each derivative labeled with 177Lu and incubated in
human serum. The half-lives derived from fitting the ex-
perimental data are reported in Table 2. There were
some clear differences among the tested compounds, in-
dicating that the amino acid substitutions performed
have important effect on compound stability.
As shown in Fig. 2, studied peptides could be grouped
according to their half-life. In Fig. 2a, serum stabilities of
the rapidly degraded peptides are reported: BN1, the na-
tive bombesin sequence that, as expected, showed very
rapid degradation with a half-life value of 16.1 h; BN3
(half-life of 40.7 h), and the BN2 and BN7 peptides
(showing half-lives around 20 h) having the Cha13-Nle14
substitution and differing only for the N-terminal DPhe.
In Fig. 2b, the serum stability profiles of the peptides
with the longer half-lives are shown (BN5, BN8, BN4,
and BN6) with the first two showing half-life values over
15 days (354.2 and 414.1 h, respectively).
Biodistribution and imaging experiments in nude mice
bearing subcutaneous PC-3 xenografts
Figure 3 shows results of biodistribution experiments
performed at 1, 6, and 24 h after injection of 111In la-
beled derivatives BN1, BN4, BN7, and BN8. The native




Kd/nM Bmax (binding sites/cell) *10
5 Half-life/h
BN1 3.30 ± 0.90 2.45 ± 0.73 16.1
BN2 4.27 ± 1.28 4.10 ± 1.23 20.9
BN3 >1000 ND 40.7
BN4 4.97 ± 1.40 5.54 ± 1.56 224.1
BN5 10.89 ± 2.71 1.56 ± 0.39 354.2
BN6 3.90 ± 1.15 5.89 ± 1.74 208.3
BN7 6.36 ± 1.74 5.32 ± 1.46 18.7
BN8 5.91 ± 1.77 3.52 ± 1.03 414.1
ND not determinable
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BN1 peptide shows very rapid blood clearance, and
already at 1 h post injection, there is very low blood ac-
tivity. High uptake is observed in the kidneys compared
to other organs. There is high level, prolonged accumu-
lation in the GRP-R-rich pancreas. The tumor-targeting
capabilities appear to be rather poor. The BN4 peptide
appears to have the longest circulating half-life of all
tested compounds with blood %ID/g in the order of 5 %
at 1 h. The compound shows some hepatobiliary clear-
ance with high %ID/g values in the intestines and
prolonged high-level kidney retention. The receptor-
positive PC-3 xenografts and pancreas showed very high
initial uptake that dropped at later time points. Due to
permanently high circulating activity, T/B ratios calcu-
lated in vivo are the least favorable of all peptides. The
BN7 peptide showed very rapid blood clearance, some
hepatobiliary excretion, and overall poor targeting to the
receptor-positive xenografts. The BN8 peptide, a com-
pound that by design should have antagonistic activity,
performed better than BN1 and BN7, with higher, at
least at the first two time points, accumulation in the
receptor-positive xenografts with low circulating activity
and highest T/B ratio in vivo (Figs. 3 and 4).
Gamma camera experiments confirmed data obtained
from organ biodistribution studies. Figure 5 shows im-
ages obtained 6 h after injection in representative mice
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Fig. 3 Biodistribution of different radiolabeled bombesin derivatives. a BN1. b BN4. c BN7. d BN8. Data are expressed as %ID/g, and error bars are
standard deviations of three mice per time point. The highest tumor uptake with low pancreas, liver, and kidney uptake is BN8
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from the four groups tested. Although the tumor is
clearly visible with all compounds tested, the BN8 com-
pound shows better imaging properties with higher con-
trast relative to surrounding tissue in the PC-3
xenografts.
Discussion
Due to its high overexpression, GRP-R is an attractive tar-
get receptor for imaging and therapy of several cancers.
Different peptides based on the wild-type BN [7–14] se-
quence, with agonist or antagonist properties, have been
described in recent years and have been characterized as
imaging tracers after their labeling with gamma or posi-
tron emitters. However, several different approaches for
peptide labeling and other modifications, such as intro-
duction of spacers between the targeting moiety and the
chelator group, have been described. This does not allow
to accurately compare and evaluate the importance of the
peptide structure for binding and imaging properties. We
have attempted to address this issue by comparing eight
BN[7–14] peptide conjugates having the same spacer and
metal chelator at N-terminus.
Based on data available in the literature, we have
selected and characterized eight DOTA coupled pep-
tide sequences that are bombesin analogs (Fig. 1).
These publications served as basis for peptide design
[15, 19, 26, 28, 29]. For the BN2 peptide, Leu13-Met14
has been substituted with Cha13-Nle14, a previously
described strategy aimed at improving peptide stabil-
ity in vivo [13]. The BN3 analog derives from the
BN2 analog and contains an additional glutamic acid
residue on the C-terminus that was introduced in an
attempt to improve solubility. In BN4, the dipeptide
Leu13-Met14 has been substituted with Sta13-Leu14 in
an effort to improve in vivo stability to aminopepti-
dase activity. The Leu13-to-Sta13 substitution has also
been shown to provide antagonistic properties to the
peptide [17]. Peptide BN5 is a further modification of
BN4 in which the Gly11 residue has been substituted
with N-methylglycine to improve stability of the Gly–
His bond to carnosinase enzymatic cleavage in vivo.
The BN6, BN7, and BN8 peptides are modifications
of the BN4, BN2, and BN5 peptides, respectively, in
which a DPhe has been introduced at the N-terminus
in order to increase binding affinity as previously
described [11]. A hydrophilic spacer, formed by four
ethoxylic groups (PEG4) was interposed between
the peptide and the DOTA chelator. This approach
has been previously described with DOTA coupled
bombesin derivatives, and this particular spacer
length was chosen based on evidence showing im-



















































Fig. 4 Tumor-to-background (T/B) ratios in mice with PC-3 xenografts injected with different radiolabeled bombesin derivatives. a BN1. b BN4. c
BN7. d BN8. The BN8 derivative shows the highest ratios among the compounds tested
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were synthesized in solid phase with Fmoc/tBu
chemistry and obtained in high purity after RP-HPLC
chromatography.
The radiolabeled peptide derivatives show no signifi-
cant differences in affinity and binding capacity on PC-3
cells, with the exception of the BN3 derivative. This
derivative has a modification on the C-terminus that
appears to completely block its ability to bind to the re-
ceptor. The dissociation constants (Kd) of the remaining
seven 111In-labeled peptides are in the nanomolar range
and are in agreement with previously published data on
this same cell line with similar derivatives [13, 19, 21]. It
has been previously reported [11] that the addition of a
DPhe residue at the N-terminus would positively affect
peptide-binding affinity; however, we did not observe
any significant increase in affinity by comparing the
DPhe coupled derivatives (BN6, BN7, and BN8) with
their respective counterparts not containing DPhe (BN4,
BN2, and BN5).
Serum stability was studied in human serum after la-
beling. Due to its weekly availability in our laboratory
(University Hospital Freiburg) in high quantity, we chose
177Lu for these experiments. There are some clear
differences among the compounds tested, indicating that
the amino acid substitutions within the binding se-
quence have important effect on peptide stability. The
native BN1 sequence shows very rapid degradation. The
fast degradation of the wild-type BN derivative (BN1) is
in agreement with the behavior observed for 177Lu-
AMBA [30] in which the same peptide sequence is
modified at the N-terminus with a 4-aminobenzoyl spa-
cer and the DO3A chelator.
The BN8 and BN5 derivatives, the two peptides contain-
ing the NMeGly11 as well as the Sta13 substitutions, show
very long plasma half-lives (over 15 days in both cases).
The two compounds differ only for the N-terminal DPhe
that appears not to affect plasma stability.
Similarly, the BN4/BN6 pair shows fairly long plasma
half-life and, also in this case, the addition of the N-
terminal DPhe does not appear to have an impact on
stability.
The BN2/BN7 pair having the Cha13-Nle14 substitu-
tion and again differing only for the N-terminal DPhe
shows superimposable plasma half-lives and the rate of
degradation is in agreement with previously reported
data on the same peptide sequence labeled with 99mTc
Fig. 5 Dorsal view gamma camera images obtained 6 h post injection. Subcutaneous tumors in the right thigh are indicated. The BN8 derivative
shows the best contrast of tumor uptake compared to other organs (mice are M5, M14, M29, and M33)
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using a different approaches [13]. These two peptides,
however, show more rapid degradation compared to the
BN5/BN8 and BN4/BN6 pairs that contain the Sta13-
Leu14 substitutions.
The high affinity binding of the seven of the tested de-
rivatives suggests they are all suitable for in vivo use as
GRP-R targeting radiopharmaceuticals. We chose only
four for further in vivo studies. The BN1 peptide served
as historical reference as it is the one from which all
other peptides are derived. Given the clear similarities in
the in vitro properties of the BN4/BN6, BN2/BN7, and
BN5/BN8 pairs, we chose one from each pair for the in
vivo studies. We therefore characterized the DPhe-con-
taining BN7 and BN8 peptides whereas the non-DPhe-
containing BN4 was chosen over the BN6 peptide as the
latter has been previously characterized in the same ani-
mal model [22]. In the interest of limiting the number of
animals and given the fact that very low nonspecific re-
tention in both the PC-3 xenografts and the receptor-
rich pancreas has been previously reported for similar
DOTA coupled peptides [26], we deliberately chose not
to perform blocking experiments.
The BN1 peptide showed very rapid blood clearance,
very high prolonged uptake in the receptor-rich pancreas,
and lower targeting of the PC-3 xenografts that was tran-
sient as it diminished over time. These biodistribution
properties are very similar to those previously described
for 177Lu-AMBA [30] that also shows prolonged specific
retention in the pancreas, transient accumulation in
receptor-positive tumor, and rapid blood clearance. The
remaining three peptides, BN4, BN7, and BN8, show some
similar pattern in biodistribution properties.
All three show transient high accumulation in the PC-
3 tumor and pancreas that drops over time. Although
tumor accumulation rapidly decreases over time, there is
still a fairly wide time window where high target-to-
background ratios were observed. The missing DPhe
residue in BN4 may be responsible for the poor pharma-
cokinetic performance of this analog compared to that
reported for the DPhe derivative [22]. The uptake in
tumor and receptor-positive organs such as the pancreas
is reasonably high at the early time point but rapidly de-
creases over time. The biodistribution profile of the His-
Cha derivative (BN7) mirrors the one reported previously
on a similar molecule with high uptake in the pancreas at
the early time point that decreases over time and with
overall fairly low tumor uptake [21]. A favorable pharma-
cokinetic profile is shown by BN8 with high tumor uptake
and good tumor-to-non-target-tissue ratios already at 1 h.
This analog is the only one showing the highest uptake in
the xenograft compared to all other organs at all times
tested. Given this feature and the advantageous target-to-
background ratios observed, this derivative seems to have
the best characteristics among the eight compounds
tested, particularly for imaging applications using short
half-lived isotopes such as 68Ga.
Conclusions
We have performed a side-by-side comparison of eight
different peptide sequences targeting the GRP-R. Our
data indicate that among the peptides tested, the BN5/
BN8 pair with the NMeGly11 and Sta13-Leu14 substitu-
tions would be the most suitable compound for rapid
high-contrast GRP-R targeting for imaging applications
in vivo.
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